SCHEDULE 13G: Beryl Capital Management Discloses 9.9% Stake in Vigil Neuroscience

Beryl Capital Management and its affiliates have disclosed a significant beneficial ownership stake of 9.9% in Vigil Neuroscience, Inc., totaling 4,606,267 shares of common stock.

Summary

• Beryl Capital Management LLC, Beryl Capital Management LP, and David A. Witkin each reported beneficial ownership of 4,606,267 shares of Vigil Neuroscience, Inc. Common Stock, representing 9.9% of the class.
• Beryl Capital Partners II LP reported beneficial ownership of 3,711,724 shares, representing 8.0% of the class.
• The percentages are calculated based on 46,671,534 shares of Common Stock outstanding on April 30, 2025, as disclosed in Vigil Neuroscience's Form 10-Q for the quarter ended March 31, 2025.
• All reported shares are held with shared voting and shared dispositive power by the respective reporting persons.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Vigil Neuroscience, Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, carrying a neutral sentiment. The acquisition of a significant stake by an institutional investor could be perceived positively by the market, but the document itself is purely informational.

Positives

• The disclosure of a significant stake by an institutional investor like Beryl Capital Management can signal confidence in Vigil Neuroscience's long-term prospects.
• The acquisition of shares in the ordinary course of business suggests a strategic investment rather than an activist intent.

Negatives

• NA

Risks

• NA

Future Outlook

This document does not contain any forward-looking statements or guidance regarding Vigil Neuroscience, Inc.'s future outlook.

Industry Context

This filing indicates a significant passive investment by Beryl Capital Management in Vigil Neuroscience, a biotechnology company. Such investments are common in the biotech sector, where institutional investors often take positions in companies with promising drug pipelines or research, signaling potential long-term value. The filing itself does not provide broader industry trends but reflects an investment decision within the sector.

Comparison to Industry Standards

• A 9.9% stake is a substantial passive investment, often seen as a threshold just below requiring more detailed Schedule 13D filings which imply activist intent. This level of ownership is typical for institutional investors seeking significant exposure without direct control.
• The structure of Beryl Capital Management LLC acting as an investment adviser and general partner to the LPs, with David A. Witkin as the control person, is a standard setup for private investment funds and their management.

Related Party Transactions

• Beryl Capital Management LLC is the investment adviser to Beryl Capital Partners II LP and other accounts.
• Beryl Capital Management LLC is the general partner of Beryl Capital Management LP, which in turn is the general partner of Beryl Capital Partners II LP and other private investment funds.
• David A. Witkin is the control person of Beryl Capital Management LLC, establishing a hierarchical relationship among the reporting entities.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor may be viewed positively, potentially increasing investor confidence and liquidity.
• Management: Awareness of a large, passive institutional holder may influence strategic decisions, though the filing explicitly states no intent to change or influence control.

Key Dates

Keywords

Vigil Neuroscience, Beryl Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Equity Stake